Yahoo Web Search

  1. AbbVie Inc. ABBV announced that it has acquired Seattle-based, privately held company Mavupharma to develop novel treatments for cancer using the latter’s STING signaling pathway ...

  2. AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

    Zacks via Yahoo FinanceJul 19 14:30 PM

    The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2019. This widely-known consensus ...

  3. AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know

    Zacks via Yahoo FinanceJul 17 13:00 PM

    AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

  4. The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

    Benzinga via Yahoo FinanceJul 20 13:53 PM

    Biotech stocks had a relatively muted performance last week. Johnson & Johnson (NYSE: JNJ) kick started the second-quarter reporting season for big pharma companies, beating forecasts and an ...

  5. AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why

    Zacks via Yahoo FinanceJul 17 12:45 PM

    Our proprietary system currently recommends AbbVie (ABBV) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Earnings growth is ...

  6. 3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

    Zacks via Yahoo FinanceJul 18 21:23 PM

    Johnson & Johnson’s JNJ second-quarter 2019 results were better-than-expected. Organically, excluding the impact of acquisitions and divestitures, sales increased 3.7% on an operational basis ...

  7. AC Immune Initiates Phase I Study for Alzheimer's Disease

    Zacks via Yahoo FinanceJul 18 14:26 PM

    AC Immune SA ACIU announced that it has dosed the first subject in the phase I study of ACI-3024, a first-in-class, investigational, oral, small molecule Tau Morphomer inhibitor, for the treatment ...

  8. AbbVie (ABBV) Gains But Lags Market: What You Should Know

    Zacks via Yahoo FinanceJul 15 21:45 PM

    AbbVie (ABBV) closed the most recent trading day at $70.29, moving +0.01% from the previous trading session. In that same time, the Medical sector lost 0.79%, while the S&P 500 gained ...

  9. This week marked the start of the second-quarter earnings season for the pharma space with J&J JNJ and Novartis NVS releasing their results. Inside J&J & Novartis’ Q2 Earnings: J&J beat estimates ...

  10. Novartis's Pure Play in Pharma Works, for Now

    Bloomberg via Yahoo FinanceJul 18 14:34 PM

    CEO Vas Narasimhan has refocused the Swiss pharma giant around drugs by selling off eye-care business Alcon and its remaining consumer-health interests. There are high expectations for continuing growth, but they come with significant risks.

  1. Ad
    related to AbbVie Inc